In addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Rumors

Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal April 18, 2016 11:38 AM Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - StifelApril 18, 2016 9:59 AM Starboard Comments on Depomed's (DEPO) Move to Withdraw Reincorporation Proposal; Remains 'Highly Concerned'April 15, 2016 7:18 AM Acadia Pharma (ACAD) Higher as Leerink Highlights as Partnership and Acquisition TargetApril 14, 2016 9:57 AM